Evidence map›Paper›PMID 32734217›Full record

ArticleKidney medicine

Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study.

Ioan-Andrei Iliuta, Beili Shi, Marina Pourafkari, Pedram Akbari, Giancarlo Bruni, Ralph Hsiao, Steffan F Stella, Korosh Khalili, Eran Shlomovitz, York Pei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. KDIGO 2025 ADPKD guideline: a commentary on diagnosis and management of hepatopancreatic manifestations by the ERA Working Group Genes & Kidney.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  5. Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ioan-Andrei IliutaDivision of Nephrology, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Beili ShiDivision of Nephrology, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Marina PourafkariDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Pedram AkbariDivision of Nephrology, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Giancarlo BruniDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ralph HsiaoDivision of General Surgery, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Steffan F StellaDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Korosh KhaliliDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Eran ShlomovitzDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, Ontario, Canada.
York PeiDivision of Nephrology, University Health Network and University of Toronto, Toronto, Ontario, Canada.
University Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveAutosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder. Progressive increase in cyst number and size leads to kidney failure in a majority of patients. Large kidney cysts, although few, can be especially deleterious by impeding kidney blood flow and obstructing urine flow over a large region. Foam sclerotherapy is a minimally invasive procedure that may be used to ablate large cysts. We examined the effectiveness and safety of foam sclerotherapy for kidney volume reduction in patients with ADPKD. STUDY

designProspective cohort study. SETTING &

participantsAdults with ADPKD at a tertiary referral center in Toronto. PREDICTOR: Foam sclerotherapy. OUTCOMES: Volume of treated kidneys and adverse events. ANALYTICAL APPROACH: Treated and nontreated kidney volume, kidney function, tolerability, and symptoms were analyzed within each patient.

resultsWe performed 77 foam sclerotherapy treatment sessions in 66 patients. Foam sclerotherapy was associated with a 21.8% volume reduction of the treated kidneys (n = 95; median, 1,138 [IQR, 801-1,582] mL before vs 891 [IQR, 548-1,450] mL after; LIMITATIONS: Small sample, observational data.

conclusionsFoam sclerotherapy is a safe and effective procedure for kidney volume reduction and amelioration of compressive symptoms in select patients with ADPKD. Further studies are needed to assess its effects on kidney blood flow and kidney function and determine the subgroups of patients most likely to benefit.

Indexed as

autosomal dominant polycystic kidney diseasecyst ablationFoam sclerotherapykidney volume reduction

Identifiers

PMID32734217
PMCPMC7380421
OpenAlexW2980920619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.